γ-Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome.

Xu-Qiao ChenAnn BeckerRicardo AlbayPhuong D NguyenDmitry KarachentsevAmanda J RobertsKevin D RynearsonRudolph E TanziWilliam C Mobley

Published in: Annals of neurology (2024)

Our findings point to the involvement of increased levels of Aβ42 and/or Aβ40 in contributing to several molecular and cognitive traits associated with DS-AD. They speak to increased dosage of the APP gene acting through heightened levels of Aβ42 and/or Aβ40 as supporting pathogenesis. These findings further the interest in the potential use of γ-secretase modulators for treating and possibly preventing AD in individuals with DS. ANN NEUROL 2024.

Keyphrases

mouse model
genome wide
small molecule
copy number
cognitive decline
dna methylation
gene expression
risk assessment
human health